📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
27 announcements match the current filters (relevance ≥ 5).
Acutaas Chemicals Reports FY25 Revenue of ₹9,898 Million and 25% Capacity Expansion
Acutaas Chemicals Limited, formerly known as Ami Organics, has released its Annual Sustainability Report for FY 2024-25, reporting a standalone revenue of ₹9,898 million. The company achieved a significant 25% increase in production capacity, primarily driven by its Ankleshwar facility. Strategically, the firm is expanding into high-value sectors including semiconductor-grade chemistries and battery materials. On the ESG front, it earned the EcoVadis Platinum Medal, placing it in the top 1% of companies globally, and operationalized 15.8 MW of solar capacity.
Key Highlights
Standalone revenue reached ₹9,898 million with consolidated revenue surpassing ₹1,000 crore
Production capacity increased by 25% during the fiscal year, led by the Ankleshwar unit
Achieved EcoVadis Platinum Medal and operationalized 15.8 MW of solar power capacity
Portfolio expanded to over 610 chemistries with exports to more than 55 countries
Zero conflict-of-interest cases and zero POSH complaints reported for the year
👀 What to Watch
Investors should note the company's successful transition to its new identity and its strong ESG positioning which may attract institutional capital. The 25% capacity expansion and move into semiconductor chemicals provide a positive outlook for medium-term growth.
Acutaas Chemicals Q3 FY26 Net Profit Surges 139% YoY to ₹108.6 Cr; Revenue Up 42%
Acutaas Chemicals (formerly Ami Organics) reported a stellar performance for Q3 FY26, with consolidated revenue growing 42.3% YoY to ₹391.2 crore. Net profit for the quarter witnessed a massive jump of 139% YoY, reaching ₹108.6 crore compared to ₹45.4 crore in the previous year. For the nine-month period, the company has already surpassed its full-year FY25 profit, recording ₹222.1 crore. The company also highlighted a strategic investment of ₹130.80 crore in its South Korean joint venture, Indichem Inc., to bolster its specialty chemicals portfolio.
Key Highlights
Consolidated Revenue from operations rose 42.3% YoY to ₹39,118.33 Lakhs in Q3 FY26.
Net Profit surged by 139% YoY to ₹10,863.62 Lakhs, driven by strong operational efficiency.
Basic EPS for the quarter stood at ₹13.12, up from ₹5.42 in the corresponding quarter of the previous year.
The company invested ₹130.80 crore in South Korean JV Indichem Inc., holding a 75% stake through its subsidiary.
9-month consolidated profit reached ₹22,208.56 Lakhs, a 127% increase over the ₹9,770.16 Lakhs recorded in 9M FY25.
👀 What to Watch
The company is exhibiting robust earnings momentum and successful execution of its global expansion strategy. Investors should maintain a positive outlook while monitoring the integration of the South Korean JV and the impact of the newly granted ESOPs on future employee costs.
Acutaas Chemicals Q3 FY26 PAT Surges 133.7% YoY to ₹1,062 Mn; Revenue Up 43%
Acutaas Chemicals reported a stellar performance for Q3 FY26, with revenue growing 43% YoY to ₹3,932 million. The company achieved a significant milestone as quarterly PAT crossed ₹1,000 million for the first time, reaching ₹1,062 million. Profitability margins saw substantial expansion, with EBITDA margins jumping to 38.3% from 25.0% in the previous year. Management has also raised its full-year revenue growth guidance from 25% to approximately 30%, citing strong momentum in the CDMO business and upcoming verticals like battery and semiconductor chemicals.
Key Highlights
Revenue from operations grew 43% YoY to ₹3,932 million, driven by the CDMO business ramp-up.
Net Profit (PAT) skyrocketed by 133.7% YoY to ₹1,062 million, crossing the ₹1,000 million quarterly milestone.
EBITDA margins expanded significantly by 1,330 bps YoY to reach 38.3% compared to 25.0% in Q3FY25.
Full-year revenue growth guidance revised upward from 25% to approximately 30% for FY26.
Gross margins improved to 57.0%, up 1,073 bps YoY, reflecting a superior product mix and operational efficiency.
👀 What to Watch
Investors should take note of the significant margin expansion and the management's confidence reflected in the upward guidance revision. The company's strategic pivot into semiconductor and battery chemicals offers strong long-term growth catalysts beyond its core pharmaceutical business.
Acutaas Chemicals Q3 FY26 PAT Surges 133.7% YoY to ₹1,062 Mn; Revenue Guidance Raised to 30%
Acutaas Chemicals reported a stellar Q3 FY26 performance with revenue growing 43% YoY to ₹3,932 million, driven by a robust ramp-up in the CDMO business. Profitability saw a massive jump as EBITDA rose 119.4% to ₹1,507 million, with margins expanding significantly to 38.3% due to favorable product mix and operating leverage. Consequently, PAT grew by 133.7% YoY to reach ₹1,062 million, the highest ever for the company. Management has revised its full-year revenue growth guidance upward to approximately 30% based on a strong order book and improved visibility.
Key Highlights
Revenue from operations grew 43% YoY to ₹3,932 million in Q3 FY26.
EBITDA margins expanded by 1,330 bps YoY to 38.3%, leading to EBITDA of ₹1,507 million.
Net Profit (PAT) increased by 133.7% YoY to ₹1,062 million with a 27% margin.
Management raised FY26 revenue growth guidance from 25% to approximately 30%.
Advanced Intermediates segment remains the primary driver, contributing ₹3,511 million to revenue.
👀 What to Watch
Investors should view the significant margin expansion and guidance upgrade as a strong bullish signal. The company's strategic pivot into high-growth battery and semiconductor chemicals provides a long-term growth runway.
Acutaas Chemicals Reports Q3 FY26 Results; Auditor Issues Clean Review Report
Acutaas Chemicals Limited, formerly known as Ami Organics Limited, has submitted its standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The independent auditor, Maheshwari & Co., has issued a clean review report, indicating no material misstatements in the financial statements. The consolidated results encompass various subsidiaries including Acutaas Chemicals Electrolytes and Acutaas Advance Material, as well as joint ventures. This filing confirms the company's adherence to SEBI's regulatory reporting requirements.
Key Highlights
Acutaas Chemicals (formerly Ami Organics) filed financial results for the period ended December 31, 2025.
Independent Auditor Maheshwari & Co. issued an unmodified review report for both standalone and consolidated financials.
The consolidated entity includes subsidiaries such as Baba Fine Chemicals and step-down subsidiaries like Indichem Inc.
Financial statements were prepared in accordance with Ind AS 34 (Interim Financial Reporting) and SEBI Regulation 33.
The board meeting for the approval of these results was concluded on January 28, 2026.
👀 What to Watch
Investors should review the detailed profit and loss statements once fully published to assess revenue and margin performance. The clean audit report provides confidence in the company's financial reporting integrity.
Acutaas Chemicals Inaugurates Phase 1 Battery Chemicals Block at Jhagadia Facility
Acutaas Chemicals Limited has officially inaugurated Phase 1 of its new state-of-the-art manufacturing block at the Unit-III Jhagadia facility in Gujarat. This dedicated facility will focus on producing electrolyte additives and other battery chemicals, marking a significant expansion into the high-growth EV supply chain. The inauguration took place on January 19, 2026, following an initial project intimation in December 2024. This move aligns with the company's strategy to diversify its specialty chemical portfolio into the energy storage sector.
Key Highlights
Inauguration of Phase 1 of a dedicated manufacturing block for electrolyte additives and battery chemicals.
The facility is located at the existing Unit-III Jhagadia site at Plot No. 910/1/B, G.I.D.C., Gujarat.
The expansion follows through on the company's strategic plan initiated on December 11, 2024.
The new block is described as a 'State of the Art' facility targeting the specialized battery materials market.
👀 What to Watch
Investors should view this as a positive development for long-term growth in the specialty chemicals space. Monitor the ramp-up of production and the subsequent impact on revenue and margins in the upcoming fiscal quarters.
Acutaas Chemicals Credit Rating Reaffirmed at CARE A+/Stable/CARE A1+
CARE Ratings has reaffirmed the credit ratings for Acutaas Chemicals Limited. The long-term/short-term bank facilities are rated CARE A+; Stable / CARE A1+. The total amount of facilities rated is ₹135.00 crore, enhanced from ₹125 crore. This reaffirmation indicates CARE's continued confidence in Acutaas Chemicals' ability to meet its financial obligations.
Key Highlights
Long Term / Short Term Bank Facilities rated CARE A+; Stable / CARE A1+
Total facilities rated amount to ₹135.00 crore
Facilities enhanced from ₹125 crore
Rating reaffirmed by CARE Ratings Limited
👀 What to Watch
The reaffirmation of credit ratings suggests stability in the company's financial position. Investors should monitor the company's performance and any further rating updates from CARE Ratings.
